[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE515515T1 - Immunglobuline gegen menschlisches osm - Google Patents

Immunglobuline gegen menschlisches osm

Info

Publication number
ATE515515T1
ATE515515T1 AT05733043T AT05733043T ATE515515T1 AT E515515 T1 ATE515515 T1 AT E515515T1 AT 05733043 T AT05733043 T AT 05733043T AT 05733043 T AT05733043 T AT 05733043T AT E515515 T1 ATE515515 T1 AT E515515T1
Authority
AT
Austria
Prior art keywords
immunolobulins
against human
human osm
osm
immunolobulins against
Prior art date
Application number
AT05733043T
Other languages
English (en)
Inventor
Jonathan Henry Ellis
Alexandre Eon-Duval
Volker Germaschewski
Christopher Plumpton
Nicholas Timothy Rapson
Michael Robert West
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0407193A external-priority patent/GB0407193D0/en
Priority claimed from GB0407197A external-priority patent/GB0407197D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE515515T1 publication Critical patent/ATE515515T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT05733043T 2004-03-30 2005-03-29 Immunglobuline gegen menschlisches osm ATE515515T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0407193A GB0407193D0 (en) 2004-03-30 2004-03-30 Immunoglobulins
GB0407197A GB0407197D0 (en) 2004-03-30 2004-03-30 Immunoglobulins
PCT/GB2005/001147 WO2005095457A2 (en) 2004-03-30 2005-03-29 Immunoglobulins

Publications (1)

Publication Number Publication Date
ATE515515T1 true ATE515515T1 (de) 2011-07-15

Family

ID=35064447

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05733043T ATE515515T1 (de) 2004-03-30 2005-03-29 Immunglobuline gegen menschlisches osm

Country Status (25)

Country Link
US (2) US7858753B2 (de)
EP (2) EP2404935A1 (de)
JP (1) JP4809828B2 (de)
KR (1) KR100942849B1 (de)
AR (1) AR048516A1 (de)
AT (1) ATE515515T1 (de)
AU (1) AU2005229457B2 (de)
BR (1) BRPI0509367A (de)
CA (1) CA2562953A1 (de)
CY (1) CY1112192T1 (de)
DK (1) DK1730191T3 (de)
HK (1) HK1103747A1 (de)
HR (1) HRP20110657T1 (de)
IL (1) IL178119A0 (de)
MA (1) MA28541B1 (de)
NO (1) NO20064886L (de)
NZ (1) NZ550225A (de)
PE (1) PE20060287A1 (de)
PL (1) PL1730191T3 (de)
PT (1) PT1730191E (de)
RU (5) RU2429245C2 (de)
SG (1) SG151292A1 (de)
SI (1) SI1730191T1 (de)
TW (1) TWI365746B (de)
WO (1) WO2005095457A2 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
KR101667623B1 (ko) 2005-11-30 2016-10-19 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
ES2527661T3 (es) 2005-11-30 2015-01-28 Abbvie Inc. Método de exploración, proceso para purificar oligómeros Abeta no difundibles, anticuerpos selectivos contra dichos oligómeros Abeta no difundibles y un proceso para fabricar dichos anticuerpos
WO2007098547A1 (en) * 2006-03-01 2007-09-07 Apollo Life Sciences Limited A molecule and chimeric molecules thereof
US8133978B2 (en) * 2006-05-25 2012-03-13 Glaxo Group Limited Humanised anti-interleukin-18 antibody
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (de) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Verfahren zur behandlung von amyloidosen
MX2011000117A (es) 2008-07-10 2011-02-25 Toray Industries Composicion farmaceutica para tratamiento y prevencion de cancer.
BRPI0911926A2 (pt) 2008-08-05 2020-08-18 Toray Industries, Inc composições farmacêuticas, anticorpos e usos de um anticorpo ou um fragmento do mesmo.
EP2328934A4 (de) * 2008-08-26 2013-04-03 Macrogenics Inc T-zell-rezeptorantikörper und verfahren zu ihrer verwendung
US8309688B2 (en) * 2008-12-30 2012-11-13 Centocor Ortho Biotech Inc. Monkey homolog of human oncostatin M and methods of use thereof
EP2258723A1 (de) * 2009-06-02 2010-12-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Behandlung von Onkostatin-M-Rezeptor-ß-vermitteltem Herzversagen
PT2532365T (pt) 2010-02-04 2016-07-28 Toray Industries Composição farmacêutica para o tratamento e/ou a prevenção do cancro
WO2011096533A1 (ja) 2010-02-04 2011-08-11 東レ株式会社 癌の治療及び／又は予防用医薬組成物
CA2788718C (en) 2010-02-04 2019-05-21 Shinichi Kobayashi Caprin-1 antibody for treating and/or preventing cancer
RU2567657C2 (ru) 2010-02-04 2015-11-10 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
US8911740B2 (en) 2010-02-04 2014-12-16 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
CN102933601B (zh) 2010-04-15 2016-06-08 Abbvie公司 β淀粉样蛋白结合蛋白
CN103298833B (zh) 2010-08-14 2015-12-16 Abbvie公司 β淀粉样蛋白结合蛋白
BR112013009083B1 (pt) * 2010-10-13 2021-08-10 Janssen Biotech, Inc. Anticorpos humanos para oncostatina m, seu processo de fabricação, fragmento de ligação a antígeno, composição farmacêutica, polinucleotídeo isolado, célula hospedeira recombinante estavelmente transformada ou transfectada
BR112013012627A2 (pt) * 2010-11-23 2016-10-04 Glaxo Group Ltd proteína de ligação de antígeno, polinucleotídeo, composição farmacêutica, e uso da referida composição
MX348581B (es) 2011-08-04 2017-06-20 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
CN103764825B (zh) 2011-08-04 2015-09-02 东丽株式会社 癌的治疗和/或预防用药物组合物
PT2740794T (pt) 2011-08-04 2018-06-14 Toray Industries Composição farmacêutica para o tratamento e/ou profilaxia de cancro
RU2639522C2 (ru) 2012-02-21 2017-12-21 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
US9273130B2 (en) 2012-02-21 2016-03-01 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
JP6187256B2 (ja) 2012-02-21 2017-08-30 東レ株式会社 癌の治療及び／又は予防用医薬組成物
BR112014021103A2 (pt) 2012-02-21 2019-10-15 Toray Industries, Inc Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
EP2832365B1 (de) 2012-03-30 2017-11-01 Toray Industries, Inc. Pharmazeutische zusammensetzung zur behandlung und/oder prävention von leberkrebs
CA2869123C (en) 2012-03-30 2021-03-16 Toray Industries, Inc. Pharmaceutical composition comprising anti-caprin-1 antibodies for the treatment of gallbladder cancer
NZ753995A (en) 2013-05-30 2022-07-01 Kiniksa Pharmaceuticals Ltd Oncostatin m receptor antigen binding proteins
US9862774B2 (en) 2013-08-09 2018-01-09 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
US9550828B2 (en) 2013-09-05 2017-01-24 Boise State University Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders
KR102056963B1 (ko) 2013-12-30 2019-12-17 에피맙 바이오테라퓨틱스 인코포레이티드 Fabs-인-탠덤 면역글로불린 및 이의 용도
KR20240155987A (ko) * 2014-02-24 2024-10-29 다케다 게엠베하 Uti 융합 단백질
WO2016046738A1 (en) * 2014-09-24 2016-03-31 Università Degli Studi Di Padova Composition to induce bone marrow stem cell mobilization
EP3250925B1 (de) * 2015-01-29 2019-04-10 Ares Trading S.A. Immunoassays für hochpositiv geladene proteine
US11421028B2 (en) 2016-02-06 2022-08-23 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
KR102457956B1 (ko) 2016-03-28 2022-10-24 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
GB201614627D0 (en) * 2016-08-30 2016-10-12 Glaxosmithkline Ip Dev Ltd Antigen binding proteins
JP7368453B2 (ja) 2018-05-03 2023-10-24 シャンハイ エピムアブ バイオセラピューティクス カンパニー リミテッド Ｐｄ－１およびｌａｇ－３に対する高親和性抗体ならびにそれらから作製された二重特異性結合タンパク質
FR3090637A1 (fr) * 2018-12-21 2020-06-26 Universite De Poitiers Protéine de liaison spécifique capable de se lier spécifiquement à l’oncostatine M humaine (hOSM) et ses utilisations.
US11633457B2 (en) 2019-04-11 2023-04-25 Boise State University Pharmaceutical compositions comprising oncostatin m (OSM) antagonist derivatives and methods of use

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
EP0402226A1 (de) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformationsvektoren für Hefe Yarrowia
NZ243706A (en) 1991-07-25 1994-08-26 Idec Pharma Corp Recombinant monkey antibodies, pharmaceutical compositions
AU665025B2 (en) 1991-09-23 1995-12-14 Cambridge Antibody Technology Limited Production of chimeric antibodies - a combinatorial approach
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
ATE183513T1 (de) 1993-06-03 1999-09-15 Therapeutic Antibodies Inc Herstellung von antikörperfragmenten
JP3622208B2 (ja) 1993-06-11 2005-02-23 東ソー株式会社 骨粗鬆症治療方法及び治療薬
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
GB9806530D0 (en) * 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
CA2327505A1 (en) 1998-04-28 1999-11-04 Smithkline Beecham Corporation Monoclonal antibodies with reduced immunogenicity
CA2491864C (en) 2001-07-12 2012-09-11 Jefferson Foote Super humanized antibodies
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells

Also Published As

Publication number Publication date
RU2009108148A (ru) 2010-09-20
MA28541B1 (fr) 2007-04-03
BRPI0509367A (pt) 2007-09-11
RU2006134477A (ru) 2008-05-10
SG151292A1 (en) 2009-04-30
DK1730191T3 (da) 2011-10-17
US20110245470A1 (en) 2011-10-06
PT1730191E (pt) 2011-10-04
EP1730191B1 (de) 2011-07-06
JP2007530068A (ja) 2007-11-01
TWI365746B (en) 2012-06-11
EP1730191A2 (de) 2006-12-13
KR100942849B1 (ko) 2010-02-17
CA2562953A1 (en) 2005-10-13
RU2429245C2 (ru) 2011-09-20
PE20060287A1 (es) 2006-05-16
JP4809828B2 (ja) 2011-11-09
WO2005095457A3 (en) 2006-04-27
NO20064886L (no) 2006-12-12
NZ550225A (en) 2010-11-26
SI1730191T1 (sl) 2011-11-30
RU2009108147A (ru) 2010-09-20
AR048516A1 (es) 2006-05-03
US20070286861A1 (en) 2007-12-13
US7858753B2 (en) 2010-12-28
HK1103747A1 (en) 2007-12-28
TW200602079A (en) 2006-01-16
RU2009108149A (ru) 2010-09-20
RU2011121419A (ru) 2012-12-10
EP2404935A1 (de) 2012-01-11
CY1112192T1 (el) 2015-12-09
AU2005229457A1 (en) 2005-10-13
IL178119A0 (en) 2006-12-31
AU2005229457B2 (en) 2010-11-25
WO2005095457A2 (en) 2005-10-13
PL1730191T3 (pl) 2011-12-30
KR20060135049A (ko) 2006-12-28
HRP20110657T1 (hr) 2011-10-31

Similar Documents

Publication Publication Date Title
ATE515515T1 (de) Immunglobuline gegen menschlisches osm
NL301229I2 (nl) Deoxycholaat
DE602005026825D1 (de) Endoskop
DK2298237T3 (da) Hjerteprotese
DE502005004847D1 (de) Prothesenvorrichtung
DE602005018315D1 (de) Rollstuhl
DE602004014547D1 (de) Funduskamera
DE602005026361D1 (de) Make-up Zubereitung
ATE432082T1 (de) Impfstoff gegen periodontale krankheit
FI20050836A (fi) Röntgenlaite
DE502004010641D1 (de) Atemschutzmaske
DE602005026124D1 (de) Endoskop
AT500198B8 (de) Ladewagen
ITBO20050375A1 (it) Riunito dentale
SE0400530L (sv) Förfarande
ITBO20040302A1 (it) Riunito dentale
AT500249A3 (de) Scheibenegge
DE502005004692D1 (de) Massageaufsatz
AT501354A3 (de) Atemmaske
FR2870105B1 (fr) Laryngoscope
AT500956B8 (de) Personenschleuse
ITBO20040451A1 (it) Riunito dentale
NO20042504D0 (no) Tannpleieutstyr
SE0402392D0 (sv) New use
SE0401715D0 (sv) New use

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1730191

Country of ref document: EP